Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tamsulosin
Drug ID BADD_D02113
Description Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common.[Label] It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy.[Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.[Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.[A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238]
Indications and Usage Used in the treatment of signs and symptoms of benign prostatic hyperplasia (reduction in urinary obstruction and relief of associated manifestations such as hesitancy, terminal dribbling of urine, interrupted or weak stream...etc.)
Marketing Status Prescription
ATC Code G04CA02
DrugBank ID DB00706
KEGG ID D08560
MeSH ID D000077409
PubChem ID 60147
TTD Drug ID D05MBZ
NDC Product Code Not Available
Synonyms Tamsulosin | LY 253352 | LY-253352 | Tamsulosin Hydrochloride | 5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide | Flomax | YM 617 | YM-617
Chemical Information
Molecular Formula C20H28N2O5S
CAS Registry Number 106138-88-9
SMILES CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.000139%Not Available
Abdominal distension07.01.04.0010.000139%
Abdominal pain07.01.05.0020.000232%
Abdominal pain lower07.01.05.0100.000093%Not Available
Abnormal dreams19.02.03.001; 17.15.02.0010.000186%Not Available
Aggression19.05.01.0010.000093%Not Available
Agitation19.06.02.001; 17.02.05.0120.000093%
Altered state of consciousness19.07.01.003; 17.02.04.0010.000139%Not Available
Amblyopia06.02.01.001--Not Available
Amnesia19.20.01.001; 17.03.02.0010.000093%
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.0020.000232%
Appendicitis11.01.07.001; 07.19.01.0010.000093%
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.0010.000464%Not Available
Asthma22.03.01.002; 10.01.03.0100.000093%Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.0050.000139%
Benign prostatic hyperplasia21.04.02.0010.000186%Not Available
Blood glucose increased13.02.02.0020.000093%Not Available
Blood potassium decreased13.11.01.0100.000093%Not Available
Blood pressure decreased13.14.03.0020.000093%Not Available
Blood pressure diastolic decreased13.14.03.003--Not Available
Blood pressure systolic decreased13.14.03.007--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.0020.000093%Not Available
Burning sensation17.02.06.001; 08.01.09.0290.000093%Not Available
Cataract06.06.01.0010.000279%
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages